South Africa has received its first supply of Lenacapavir, a new HIV prevention medicine that could change how people stay protected.
Around 37 920 doses arrived in the country last week (Thursday, 02 April 2026).
What makes Lenacapavir (or LEN) different is its format. It is a six-monthly injectable, designed to reduce the need for daily prevention routines and improve consistency, making it a simpler option compared to daily pills or bi-monthly shots.
With its long-lasting effect, Lenacapavir could transform HIV prevention in South Africa by cutting down on routine clinic visits.
The Department of Health says this forms part of “integrated” and “people-centred” prevention efforts, aimed at making options more practical and easier to stick to.
Described as “one of the most exciting HIV prevention advances in years,” the medicine is expected to support those most at risk, including young women and other vulnerable groups.
The bigger goal is clear: reduce new infections and help end AIDS as a public health threat by 2030, while maintaining progress beyond that timeline.
The department has confirmed that an official launch will be announced soon, with a phased rollout plan expected to follow under the guidance of Health Minister Dr Aaron Motsoaledi.
